Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 6; no. 5; pp. 581 - 583
• Main Authors: Tagariello, G, De Biasi, E, Gajo, G B, Risato, R, Radossi, P, Davoli, P G, Traldi, A
• Format: Journal Article
• Language: English
• Published: Oxford UK Blackwell Science Ltd 01-09-2000
• Subjects: Adult; Arthroplasty, Replacement, Hip - adverse effects; Arthroplasty, Replacement, Hip - methods; Blood Loss, Surgical - prevention & control; continuous infusion; Factor VIIa - administration & dosage; Factor VIII - adverse effects; Factor VIII - immunology; haemophilia; Hemophilia A - complications; Hemophilia A - drug therapy; Hemophilia A - surgery; Hemostasis - drug effects; Humans; Infusions, Parenteral; inhibitors; Isoantibodies - blood; Male; Recombinant Proteins - administration & dosage; rFVIIa; Sodium Chloride - administration & dosage; Tranexamic Acid - administration & dosage
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1046/j.1365-2516.2000.00400.x

In this report we describe our experience of total hip replacement in two patients with severe haemophilia A and high titres of inhibitors to FVIII. We used rFVIIa replacement therapy by continuous infusion to perform the surgery. The total amount of rFVIIa used in these two patients was very similar but the manner of administration was quite different. In our experience, it is an advantage to use a higher dose for shorter periods than a lower dose for a longer treatment period. Tranexamic acid by continuous infusion, and parallel saline infusion were useful for good haemostasis and avoided local thrombophlebitis in the side of rFVIIa infusion.